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Abstract 
 
Background: Intensive insulin therapy is an aggressive treatment approach to control the blood sugar levels of 
diabetic patient. Multiple daily injection (MDI) therapy and continuous subcutaneous insulin infusion (CSII) are 
current methods of it. Intensive insulin therapy requires close monitoring of blood sugar levels along with multiple 
doses of insulin.Aims and Objective: To compare the CSII of insulin aspart with MDI of insulin aspart / insulin 
glargine in type 1 diabetic (T1DM) patients previously treated with CSII.Materials and Methods:  Eighty T1DM 
patients were randomly selected. Initially for first week all subjects were kept on insulin aspart by CSII. After one 
week 40 subjects shifted to MDI therapy i.e. insulin aspart before meal and insulin glargine at bedtime and 40 
subjects remained with CSII. After 5 weeks of first treatment subjects were shifted to the alternate treatment for 5 
weeks. During the last week of each treatment blood glucose was monitored for 48 to 72 h continuously.Results: 
Mean serum fructosamine levels were significantly lower after CSII therapy than after MDI therapy (343 ± 47 vs. 
355 ± 50 µmol/l, respectively; P = 0.0001). Continuous glucose monitoring profiles over a 24-h time period showed 
that glucose exposure was 24 and 40% lower for CSII than MDI. Hypoglycemic episodes were reported as 92% in 
CSII and 94% in MDI.Conclusion: Subject on CSII therapy with insulin aspart showed lower glycemic exposure 
without enhanced risk of hypoglycemia, as compared to the subjects on MDI with insulin aspart and insulin 
glargine. 
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Introduction 
 
 
 
Multiple daily injection (MDI) therapy and continuous 
subcutaneous insulin infusion (CSII) with an external 
pump are prominent ways of intensive insulin therapy 
(IIT) for diabetes mellitus. 
______________________ 
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Multiple daily injection (MDI) therapy and continuous 
subcutaneous insulin infusion (CSII) with an external 
pump are prominent ways of intensive insulin therapy 
(IIT) for diabetes mellitus. MDI therapy included the 
bolus injection of short or rapid-acting insulin at each 
meal, along with long acting insulin once or twice a 
day for basal insulin coverage. [1] Rapid-acting insulin 
analogue are administered as meal-time boluses to 
control the postprandial glycemic excursions are 
proven to be more effective than human insulin.[1] The 
long-acting insulin analogue, insulin glargine has long 
pharmacodynamics that makes it suitable to use as a 
basal insulin. [2]CSII therapy is getting popularity due 
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to its established efficacy, improved pump technology 
and patient preference. Sometimes patients on CSII 
therapy discontinuesit temporarily because of pump 
malfunction, skin problems or physical activity. During 
such periods, type 1 diabetic patients (T1DM) 
switching to MDI therapy could continue to use insulin 
aspart as the mealtime insulinand could use insulin 
glargine as the basal insulin. [3]Past researches have 
proven that the CSII is equivalent to and a lot more 
effective than MDI therapy. The use of an analogue 
only MDI regimen consisting of basal glargine and 
meal time rapid-acting analogue has been nick named 
as “poor man’s pump. [3] 
Hence, in present study we tried to compare CSII of 
insulin aspart with MDI of insulin aspart / insulin 
glargine in T1DM patients previously treated with CSII 
 
Material and Method 
 
It was a cross sectional observational study which ran 
for 10 weeks. It was divided in to two periods during 
which outcomes of CSII therapy on T1DM patients 
were compared with outcomes of MDI therapy in two 
5-weeks treatment periods. All 80 subjects of this study 
were T1DM patients.A written informed consent was 
obtained before the start of the present study. All 
patients were adults of age 18 years or more, having 
body mass index (BMI) less than or equal to 41 kg/m2 
and  glycated hemoglobin (HbA1c) ≤9%. All subjects 
were formerly treated with CSII for at least 100 days 
before the sampling. Subjects with weakened hepatic, 
weakened renal function, decreased cardiac function, 
hypoglycaemia or frequent hypoglycaemia were 
excluded from the study. Pregnant, breast-feeding or 
not practicing contraception were also excluded. In a 
first week of study subjects were switched from use of 
their CSII insulin to insulin aspart. The mealtime 
insulin coverage with insulin aspart during MDI and 
CSII treatments were adjusted based on the 
carbohydrate counting and a pre-prandial blood 
glucose levels. During therapy cross-over subjects were 
either emained on CSII with insulin aspart or were 
swapped to MDI therapy using a single basal bedtime 
injection of insulin glargine.Overall glycemic control 
in subjects was assessed by fructosamine 
measurements taken at the beginning and end of each 
treatment period. The normal fructosamine level range 
from 0 to 285µmol/l. HbA1c was recorded at the 
beginning and end of the study. During the last week of 
each treatment period (5 week each), subjects were 
kept on continuous monitoring to keep track of blood 
glucose.  General physical examinations were 
conducted at the beginning and end of the study and 
critical situations were monitored during the study. 
Hypoglycemic episodes were monitored as minor 
hypoglycaemic episodes (asymptomatic blood glucose 
measurement <50 mg/dl) and major hypoglycemic 
episodes (blood glucose <50 mg/dl).All the data 
analysis was [performed using IBM SPSS ver. 20 
software. Frequency distribution and cross tabulation 
was used to prepare the tables. Quantitative data is 
expressed as mean ± standard deviation (SD). Student t 
test was used to compare the means. P value of <0.05 is 
considered as significant. 
 
Results 
 
Mean HbA1c at the end of the 10th week was similar as 
at the end of each therapy period i.e. at the time of CSII 
to MDI shifting it was 7.3±0.7% and at MDI to CSII 
shifting it as 7.1± 0.7% (P>0.05). It shows that patients 
have maintained the overall glycemic control during 
both therapy periods.  
At the end of study, combined HbA1c value (7.2 ± 0.7) 
of all the patients was significantly lower than the 
baseline value of 7.5± 0.8%. 
Total daily insulin doses taken by subjects in both CSII 
and MDI treatments were similar as their baseline daily 
insulin dose.  
 
Table 1:  Comparing mean fructosamine (µmol/l) levels 
 
Treatment Sequence Baseline CSI MDI 
CSI to MDI 349± 43 350± 45 358± 48 
MDI to CSI 343±47 332± 47 347± 49 
Data is expressed as mean±SD, MDI; multiple daily injection, CSII; continuous subcutaneous insulin infusion 
Table 2: Comparing daily insulin dose (units) requirement 
Treatment Sequence Baseline CSI MDI 
CSI to MDI 42.1± 17.7 42.2±18.9 45.9± 18.1 
MDI to CSI 41.5± 16.9 39.4± 17.6 46.1± 20.5 
Data is expressed as mean ± SD, MDI; multiple daily injection, CSII; continuous subcutaneous insulin infusion 
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Out of 80 patients, 74 had experienced the hypoglycemic episodes during the CSII treatment and 73 during the MDI 
therapy (p>0.05). Five major hypoglycemic episodes were reported; two in CSII-treated patients and three in MDI-
treated subjects.  
 
Discussion 
 
Intensive diabetes management can be done either with 
the CSII or with MDI. Intensive diabetes management 
required to achieve near normal glycemia, to avoid 
short-term crises such as hypoglycemia requiring third 
part assistance or intervention, to minimize longterm 
complications and to improve the quality and length of 
life in persons suffering from diabetes. 
[4]Disadvantages of MDI are the need for patients to 
take three or even more injections per day by syringe 
or pen, resulting in poor compliance, and to use 
modified insulin intermediate or long acting insulins 
that must be injected to reach basal concentration of 
insulin to keep blood glucose within normal limits 
between meals. It has been clearly shown that 
absorption of modified insulin varies from 19% to 55% 
in the same individual, which could be the reason for 
blood glucose variability. [5]However, the absorption 
of short-acting insulins that are used in CSII varies by 
less than 3% daily. As the result of CSII insulin pump 
therapy and use of a continuous glucose sensor, 
achievement of the main goals in diabetes treatment 
could rather become an achievable task. [6, 7]In 
current study, during the 5-week cross-over therapy 
HbA1c wasn’t changed significantly in patients and 
can’t be used for concluding the efficacy of treatment. 
Though the considerably lower fructosamine values 
and significantly lower glucose during the CSII 
treatment shows that the CSII therapy with insulin 
aspart provides better glycemic control than MDI 
therapy with insulin aspart and insulin glargine.CSII 
permits the regulation of night time basal insulin rate 
and therefore it have advantage over MDI therapy by 
providing the ability to control the dawn phenomenon 
and restrain the exacerbation of postprandial 
hyperglycemia at breakfast. [8, 9]Cross sectional 
nature was the main limitation of the present study; a 
large randomized clinical trial is needed to strengthen 
the present study findings.  
 
Conclusion 
CSII was a more optimal therapy than MDI, resulting 
in lower glycemic exposure without an increased risk 
of hypoglycemia. To conclude CSII therapy with 
insulin aspart provides better glycemic control as 
compared to the MDI therapy with insulin aspart and 
insulin glargine. Statistical mean of fructosamine 
calculated after the CSII treatment for all subjects was  
 
 
considerably lesser than the calculated mean after the 
MDI therapy. 
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